ACTA ENDOCRINOLOGICA (BUC)

Introduction. Diabetic ketoacidosis (DKA) is an acute complication of diabetes mellitus, characterized by hyperglycemia, ketosis, and metabolic acidosis. This study aimed to evaluate blood and urine levels of copeptin and β-OHB in patients with DKA. Patients and methods. 49 patients with DKA and 30 healthy controls were included in the study. Serum and urine β-OHB and copeptin levels were measured using ELISA. Statistical analysis included Mann-Whitney U test, t-test, and ROC curve analysis to assess diagnostic performance. Results. Compared with controls, patients with DKA demonstrated significantly higher serum and urine β-OHB levels (p < 0.001) and lower serum copeptin levels (p < 0.001), while urine copeptin did not differ significantly (p = 0.456). Serum copeptin showed high sensitivity (98.0%) but limited specificity, whereas urine copeptin had low diagnostic value. Discussion. This study confirms β-OHB as a reliable biomarker for diagnosing DKA, with urine β-OHB offering a rapid and non-invasive alternative. Copeptin did not demonstrate diagnostic discrimination between DKA and healthy subjects. Conclusion. Quantitative measurement of serum and urine β-OHB provides superior diagnostic accuracy in DKA and should be incorporated into emergency diagnostic pathways. Copeptin may complement β-OHB in monitoring fluid status

Context. Sleeve gastrectomy is an effective method for management of obesity. The Bariatric Analysis and Reporting Outcome System (BAROS) is a comprehensive and standard system for the assessment of outcomes of weight loss surgery. It is consisted of weight loss, changes in obesityrelated comorbidities and quality of life measurements. We investigated results of the sleeve gastrectomy based on the BAROS. Material and Methods. Outcomes of laparoscopic sleeve gastrectomy surgery was studied in 45 patients with obesity (11 male, 34 female), after 45 months in Turkey. Results. Total weight loss was 26.4±0.1% of body weight at 45 months. Weight regain was seen in 97.8% of the patients with an average 14.5 kg and 13.7% body mass index points. The surgery caused 76% decrease in incidence of obstructive sleep apnea, 73% decrease in type 2 diabetes, 63% decrease in hyperlipidemia and 62% decrease in hypertension. Significant improvement is observed in all quality-of-life parameters. The final score of the BAROS was 4.23±1.02. Conclusion. Based on BAROS, sleeve gastrectomy provides significant improvements in weight loss, incidence of medical comorbidities and quality of life after surgery. Future studies should address prevention of weight regain after the surgery.